-5%
Bexitrol F contains:
- Salmeterol Xinafoate: A long-acting selective β₂-agonist providing bronchodilation for up to 12 hours
- Fluticasone Propionate: An inhaled corticosteroid with potent anti-inflammatory effects in the lungs
Salmeterol helps relieve and prevent bronchospasm, while fluticasone reduces airway inflammation, improves lung function, and decreases asthma exacerbations. This combination offers a convenient dual-action therapy.
Bexitrol F is indicated for the regular management of asthma when combination therapy is appropriate:
- Patients not adequately controlled with inhaled corticosteroids and as-needed short-acting β₂-agonists
- Patients already well controlled with both a long-acting β₂-agonist (LABA) and inhaled corticosteroid (ICS)
Use this medication only under the supervision of a registered physician.